Asunto(s)
Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Biología Computacional , Descubrimiento de Drogas , Medicamentos Herbarios Chinos/uso terapéutico , Medicina Tradicional China , SARS-CoV-2/efectos de los fármacos , Animales , Antivirales/efectos adversos , COVID-19/diagnóstico , COVID-19/virología , Medicamentos Herbarios Chinos/efectos adversos , Genómica , Interacciones Huésped-Patógeno , Humanos , Aprendizaje Automático , Terapia Molecular Dirigida , SARS-CoV-2/patogenicidadRESUMEN
DNA methylation is an important epigenetic regulator in gene expression and has several roles in cancer and disease progression. MethHC version 2.0 (MethHC 2.0) is an integrated and web-based resource focusing on the aberrant methylomes of human diseases, specifically cancer. This paper presents an updated implementation of MethHC 2.0 by incorporating additional DNA methylomes and transcriptomes from several public repositories, including 33 human cancers, over 50 118 microarray and RNA sequencing data from TCGA and GEO, and accumulating up to 3586 manually curated data from >7000 collected published literature with experimental evidence. MethHC 2.0 has also been equipped with enhanced data annotation functionality and a user-friendly web interface for data presentation, search, and visualization. Provided features include clinical-pathological data, mutation and copy number variation, multiplicity of information (gene regions, enhancer regions, and CGI regions), and circulating tumor DNA methylation profiles, available for research such as biomarker panel design, cancer comparison, diagnosis, prognosis, therapy study and identifying potential epigenetic biomarkers. MethHC 2.0 is now available at http://awi.cuhk.edu.cn/â¼MethHC.
Asunto(s)
Biomarcadores de Tumor/genética , Metilación de ADN , Bases de Datos Genéticas , Epigénesis Genética , Regulación Neoplásica de la Expresión Génica , Neoplasias/genética , Biomarcadores de Tumor/metabolismo , ADN Tumoral Circulante/sangre , ADN Tumoral Circulante/genética , Variaciones en el Número de Copia de ADN , Progresión de la Enfermedad , Elementos de Facilitación Genéticos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Internet , Análisis por Micromatrices , Anotación de Secuencia Molecular , Mutación , Neoplasias/clasificación , Neoplasias/diagnóstico , Neoplasias/metabolismo , Programas Informáticos , TranscriptomaRESUMEN
OBJECTIVE: To investigate the intervention effect of Danggui Shaoyao San on rats with cirrhotic ascites, and discuss the effect of arginine vasopressin (AVP) on cirrhotic ascites. METHOD: Male SD rats were randomly divided into the control group, the model group, Danggui Shaoyao San low, middle and high dose groups. The cirrhotic ascites rat model was established by CCl4 combined with phenobarbital. Their urines were collected at 24 h to observe urine excretion of each group. Filter papers were used to determine the amount of ascites. The levels of serum alanine aminotransferasa (ALT) , aspartate aminotransferase (AST) were detected by the automatic biochemistry analyzer. Plasma prothrombin time (PT) was evaluated by the blood coagulation analyzer. The concentration of AVP in plasma was detected by enzyme-linked immunosorbent assay (ELISA). Pathological changes in livers were observed by HE staining. RESULT: Compared with the model group, the Danggui Shaoyao San group showed significant improvement in live indexes, with notable decrease in serum ALT and AST and the time of PT, improvement in liver pathological changes. Simultaneously, the amount of ascites decreased to varying degrees, with notable increase in urine in 24 h and decrease in AVP concentration in plasma. CONCLUSION: Danggui Shaoyao San can notably improve liver functions of rats with cirrhotic ascites, reduce the generation of ascites and delay the progress of liver pathological changes. Its mechanism may be related to AVP.
